Use standardized humanized mouse models OR your specific donor whether it be HLA matching or engineered cells for immuno-oncology studies using CD34+ humanized mice on the NSG mouse background.
NSG™ mice engrafted with CD34+ hematopoietic stem/progenitor cells (HSPCs) are an attractive humanized mouse model for immune-oncology efficacy studies, as they are a validated platform that provides bone marrow engraftment with development of multi-lineage human immune cells in the peripheral blood. However, the CD34+ donors are typically selected by the mouse provider rather than by the customer. Hera offers the best of both options. For many studies, such as those with engineered cells (e.g. HSPCs and CAR-T), it may be preferential that the study sponsor dictates the donor for CD34+ humanized mice. Hera has demonstrated through effective recipient conditioning, transplantation and flow cytometric (FC) analysis efficient engraftment of engineered CD34+ HSPCs as indicated by high levels of human CD45+ chimerism in the blood and bone marrow. We offer custom donor as well as standardized donor humanized mouse studies for preclinical immuno-oncology.
Humanized mice via peripheral blood or bone marrow-derived cells
For new donors Hera suggests a pilot engraftment study be conducted
Immuno-oncology efficacy studies
Graft versus host disease (GvHD) studies
FC analysis of peripheral blood for human CD45+ at 8 weeks.
Blood collected at 8 weeks post-transplant of G-CSF mobilized peripheral blood CD34+ cells was subjected to FC analysis for human and mouse CD45. Left panel: group 1 (vehicle control); center two panels: group 2; right two panels: group 3.
FC analysis of bone marrow for human CD45+ at 8 weeks.
Bone marrow collected at 8 weeks post-transplant of G-CSF mobilized peripheral blood CD34+ cells was subjected to FC analysis for human and mouse CD45. Left panel: group 1 (vehicle control); center two panels: group 2; right two panels: group 3.